New PET tracer aims to spot Parkinson's in the brain

NCT ID NCT07640555

Recruiting now Diagnosis Sponsor: MODAG GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new radioactive tracer called [¹⁸F]MODAG-009 to see if it can safely highlight abnormal protein clumps in the brains of people with Parkinson's disease or multiple system atrophy (MSA). About 13 participants, including healthy volunteers, will receive one injection and undergo a PET scan. The main goal is to measure where the tracer collects in the brain and check for any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [¹⁸F]MODAG-009 (a radioactive tracer for PET imaging)
What this could lead to: If successful, this could lead to a new way to detect and distinguish Parkinson's disease and multiple system atrophy using brain scans.
What could go wrong: This is a very early, small study (13 people) focused on safety and imaging, not treatment. The tracer may not clearly show differences between groups or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT MULTIPLE SYSTEM ATROPHY (MSA) PARKINSON DISEASE

Contacts and locations

Locations

Institute for Neurodegenerative Disorders and XingImaging, LLC
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.